Profiel
Lisa M.
Bell worked as a Senior Director-Regulatory & Safety at Abbott Biotherapeutics Corp.
and as the Head-Regulatory & Pharmacovigilance at BioMarin Pharmaceutical, Inc. She was also the Senior Vice President- Global Regulatory Affairs at Coherus BioSciences, Inc. from 2014 to 2017.
Bell received her undergraduate and graduate degrees from Boston University and her doctorate from the University of California, Berkeley.
Eerdere bekende functies van Lisa M. Bell
| Bedrijven | Functie | Einde |
|---|---|---|
| COHERUS ONCOLOGY, INC. | Algemeen Adviseur | 01-12-2017 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Algemeen Adviseur | - |
| BIOMARIN PHARMACEUTICAL INC. | Algemeen Adviseur | - |
Opleiding van Lisa M. Bell
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coherus BioSciences, Inc.
Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
















